FRCPC

ZYUS Life Sciences Strengthens Board of Directors with the Appointment of Wayne Brownlee

Retrieved on: 
Thursday, June 29, 2023
Cannabis, Alternative Medicine, Natural Resources, Health, Pharmaceutical, Saskatchewan Order of Merit, Bachelor of Science in Human Biology, University of Toronto Faculty of Medicine, Business development, Cannabis Act, TSX Venture Exchange, University, University of Saskatchewan, Business, Public policy, Crown, Nutrien, Associate, Government, PotashCorp, Organization, Business administration, FAAP, Privatization, Retirement, Acquisition, Division, Hospital, CFO, Knowledge, Entrepreneurship, FRCPC, Chartered Professional Accountant, Health Canada, ICL Group Ltd., Management, Science, SQM, MD, Medicine

ZYUS Life Sciences Corp. ("ZYUS" or the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company leading scientific research and global development of innovative cannabinoid-based pharmaceutical drug products, is pleased to announce that Wayne Brownlee, former Vice-President and Chief Financial Officer (“CFO”) of both Potash Corporation of Saskatchewan Inc. (“PotashCorp”) and Nutrien Ltd. (“Nutrien”), has agreed to accept an appointment to ZYUS’ Board of Directors.

Key Points: 
  • ZYUS Life Sciences Corp. ("ZYUS" or the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company leading scientific research and global development of innovative cannabinoid-based pharmaceutical drug products, is pleased to announce that Wayne Brownlee, former Vice-President and Chief Financial Officer (“CFO”) of both Potash Corporation of Saskatchewan Inc. (“PotashCorp”) and Nutrien Ltd. (“Nutrien”), has agreed to accept an appointment to ZYUS’ Board of Directors.
  • Mr. Brownlee brings a wealth of knowledge, experience and expertise to his new role with ZYUS.
  • In 1989, Mr. Brownlee joined PotashCorp when it was a Crown corporation and was a catalyst for the expansion and development throughout its acquisition activity.
  • “We are extremely pleased to welcome Wayne Brownlee to ZYUS’ Board of Directors,” said Brent Zettl, President and Chief Executive Officer of the Company.

ASDS Announces Opening of 2023 Annual Meeting Registration and Preliminary Agenda

Retrieved on: 
Tuesday, June 20, 2023
Entrepreneurship, Hyatt Regency Chicago, Education, Lecture, ASDS, Hyatt Regency New Orleans, II, Dermatology, MD, MBE, Faculty, FRCPC, PDF, Bias, Society, Cadaver, Five Disciplines, Four Graces and Three Loves, Nursing

Schaumburg, IL, June 20, 2023 (GLOBE NEWSWIRE) -- The American Society for Dermatologic Surgery (ASDS) is pleased to announce the registration launch of the 2023 ASDS Annual Meeting , which will take place on Nov. 2-5 at the Hyatt Regency Chicago.

Key Points: 
  • Schaumburg, IL, June 20, 2023 (GLOBE NEWSWIRE) -- The American Society for Dermatologic Surgery (ASDS) is pleased to announce the registration launch of the 2023 ASDS Annual Meeting , which will take place on Nov. 2-5 at the Hyatt Regency Chicago.
  • Early-bird pricing allows ASDS member dermatologists to save $200 on the general registration fee when they register by Sept. 1.
  • “ASDS is committed to educational excellence, and our 2023 conference will continue to offer leading education with content on the latest innovations and opportunities for lasting connections,” said ASDS President Vince Bertucci, MD, FRCPC.
  • “Our work group has been meeting for several months to develop an engaging and robust meeting filled with leading content that will apply to the day-to-day practice of dermatologic surgeons and their office staff,” said ASDS Annual Meeting Work Group Chair H. William Higgins, II, MD, MBE.

The American Diabetes Association Commences its 83rd Scientific Sessions to Showcase Game Changing Diabetes Advances

Retrieved on: 
Monday, June 19, 2023
OASIS, Abstract, Medicine, San Diego Convention Center, PM, Type 2 diabetes, LAUNCH (Innovation Challenge), Comorbidity, JAMA, Health equity, Ageing, Quality of life, Innovation, Research, Doctor of Philosophy, Weight gain, Cardiovascular disease, Physician, Patient, Randomness, Risk, Eastern Analytical Symposium, American Diabetes Association, Treatment, AM, NAFLD, FRCPC, Health, Death, ADA, T2D, Mental health, News, Disease, Dietary supplement, Pharmaceutical industry, Soft drink, Powder metallurgy, Mobile phone, Vaccine, Tutoring, Dentistry, Obesity, MD, Lancet, Diabetes

SAN DIEGO, June 19, 2023 /PRNewswire/ -- On June 23, the American Diabetes Association® (ADA) will kick off the 83rd Scientific Sessions in San Diego, CA. The ADA's Scientific Sessions is the world's largest diabetes meeting, convening more than 12,000 leading physicians, scientists, and health care professionals from around the globe. The hybrid meeting will feature the latest scientific findings in diabetes, including more than 190 sessions and 2,000 original research presentations starting June 23 through June 26 at the San Diego Convention Center.

Key Points: 
  • Leading Diabetes Scientific Sessions Meeting Will Present Groundbreaking Data on Three Timely Tracks: Obesity Treatment, Cardiovascular Health and Latest in Diabetes Innovation
    SAN DIEGO, June 19, 2023 /PRNewswire/ -- On June 23, the American Diabetes Association® (ADA) will kick off the 83rd Scientific Sessions in San Diego, CA.
  • The ADA's Scientific Sessions is the world's largest diabetes meeting, convening more than 12,000 leading physicians, scientists, and health care professionals from around the globe.
  • During the annual meeting, the ADA is highlighting the latest cutting-edge advances in diabetes research and care.
  • Other notable topics and themes highlighted in the presentations at the 83rd Scientific Sessions include mental health, pediatric health, and health equity.

Amolyt Pharma to Host Hybrid Key Opinion Leader Event on Eneboparatide, a PTHR1 Agonist Entering Phase 3 for the Treatment of Hypoparathyroidism, in Chicago on June 16, 2023

Retrieved on: 
Wednesday, June 7, 2023
KOL, PTHR1, FACP, FACE, Hypoparathyroidism, Patient, McMaster University Medical Centre, FRCPC, Disease, Pharmaceutical industry, Calypso

The event will also be webcasted for those who are unable to attend in person.

Key Points: 
  • The event will also be webcasted for those who are unable to attend in person.
  • Patty Keating, patient and Chairwoman of the HypoPARAthyroidism Association, will share her personal experience living with the disease and challenges with the current standard of care.
  • Mark Sumeray, M.D., chief medical officer of Amolyt Pharma, will provide an update on the Calypso study, a Phase 3 clinical trial of eneboparatide for the treatment of patients with hypoparathyroidism.
  • A live question and answer session will follow the formal presentations.

ASDS Opens Registration for Its Highly Rated “Advanced Injection Techniques” Course

Retrieved on: 
Tuesday, June 6, 2023
University, Q&A, Louisiana State University, Clinical associates, Anatomy, ASDS, Skin, MBA, Tulane University, Laser, Medical director, Art, Patient safety, AMA, Faculty, FRCPC, Society, Safety, New York University Grossman School of Medicine, Veterinary medicine, Dentistry, Nursing, Dermatology, MD

The invited course faculty includes:

Key Points: 
  • The invited course faculty includes:
    Vince Bertucci, MD, FRCPC – Dr. Bertucci is the current ASDS President.
  • Deirdre Hooper, MD – Dr. Hooper is a board certified dermatologist and serves on the ASDS Board of Directors.
  • Joely Kaufman, MD – Dr. Kaufman is a board certified dermatologist at Skin Associates of South Florida and Skin Research Institute in Coral Gables.
  • Registration is $979 for ASDS residents and members and $1,279 for non-member dermatologists.

BRUKINSA® Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia

Retrieved on: 
Tuesday, May 30, 2023
Biotechnology, Health, Genetics, Clinical Trials, Oncology, CLL, SEQUOIA, BGNE, Princess Margaret Cancer Centre, The New England Journal of Medicine, Chronic lymphocytic leukemia, Hematology, Bone marrow, Master, Toxicity, BTK, SSE, The Lancet, MD, Patient, Chairperson, FRCPC, Zanubrutinib, Leukemia, Health Canada, Society, Safety, Conditional sentence, Pharmaceutical industry, BeiGene

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, announced today that BRUKINSA (zanubrutinib), a Bruton's tyrosine kinase inhibitor (BTKi), has been approved by Health Canada for the treatment of adult patients with chronic lymphocytic leukemia (CLL).

Key Points: 
  • BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, announced today that BRUKINSA (zanubrutinib), a Bruton's tyrosine kinase inhibitor (BTKi), has been approved by Health Canada for the treatment of adult patients with chronic lymphocytic leukemia (CLL).
  • “BRUKINSA now has four approved indications in Canada, demonstrating our commitment to bring this innovative BTKi treatment option to more patients across the world,” said Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at BeiGene.
  • The approval of zanubrutinib represents a significant advance for patients who can benefit from an additional treatment option,” says Raymond Vles, Board Chair, CLL Canada.
  • “More importantly, becoming informed and connecting with the CLL patient community will enable people with CLL to discuss with their doctor the treatment and dosing options that will work best for them and their lifestyle.”

Dr. Kieran Murphy Presents Results of Clinical Trial Demonstrating Positive Effect Protecting DNA From Radiation Exposure

Retrieved on: 
Saturday, May 27, 2023
Interventional, DNA, CT, Radiation, Clinical trial, Research, Nuclear medicine, CMO, Angiography, Radiology, CAIR, Capsule, Princess Margaret Hospital, X-ray, Journal, DNA repair, McMaster University, Patient, Physician, Risk, UV, Cell nucleus, University Health Network, FRCPC, Cardiology, FDA, Therapy, Health Canada, Mammography, Air pollution, Smoking, Halo, Radiation exposure, P53, Medical imaging, Dietary supplement

Dr. Kieran Murphy MD, FRCPC, FSIR, Founder, Inventor, and CMO of Cora Therapeutics, announced the efficacy of a proprietary antioxidant complex in safeguarding DNA from radiation exposure during life-saving aortic aneurysm stenting procedures guided by X-ray technology.

Key Points: 
  • Dr. Kieran Murphy MD, FRCPC, FSIR, Founder, Inventor, and CMO of Cora Therapeutics, announced the efficacy of a proprietary antioxidant complex in safeguarding DNA from radiation exposure during life-saving aortic aneurysm stenting procedures guided by X-ray technology.
  • During these high-intensity image-guided procedures, physicians were administered the antioxidant complex as two capsules, one hour prior to exposure.
  • Dr. Murphy's team has successfully demonstrated the protection of mitochondrial DNA from radiation in these subjects, marking a significant milestone in medical literature.
  • Considering that mitochondrial DNA is inherited maternally and is 13 times more vulnerable to radiation than nuclear DNA, this achievement holds tremendous promise.

Dr. Kieran Murphy Presents Results of Clinical Trial Demonstrating Positive Effect Protecting DNA From Radiation Exposure

Retrieved on: 
Saturday, May 27, 2023
Interventional, DNA, CT, Radiation, Clinical trial, Research, Nuclear medicine, CMO, Angiography, Radiology, CAIR, Capsule, Princess Margaret Hospital, X-ray, Journal, DNA repair, McMaster University, Patient, Physician, Risk, UV, Cell nucleus, University Health Network, FRCPC, Cardiology, FDA, Therapy, Health Canada, Mammography, Air pollution, Smoking, Halo, Radiation exposure, P53, Medical imaging, Dietary supplement

Dr. Kieran Murphy MD, FRCPC, FSIR, Founder, Inventor, and CMO of Cora Therapeutics, announced the efficacy of a proprietary antioxidant complex in safeguarding DNA from radiation exposure during life-saving aortic aneurysm stenting procedures guided by X-ray technology.

Key Points: 
  • Dr. Kieran Murphy MD, FRCPC, FSIR, Founder, Inventor, and CMO of Cora Therapeutics, announced the efficacy of a proprietary antioxidant complex in safeguarding DNA from radiation exposure during life-saving aortic aneurysm stenting procedures guided by X-ray technology.
  • During these high-intensity image-guided procedures, physicians were administered the antioxidant complex as two capsules, one hour prior to exposure.
  • Dr. Murphy's team has successfully demonstrated the protection of mitochondrial DNA from radiation in these subjects, marking a significant milestone in medical literature.
  • Considering that mitochondrial DNA is inherited maternally and is 13 times more vulnerable to radiation than nuclear DNA, this achievement holds tremendous promise.

Dr. Kieran Murphy Presents Results of Clinical Trial Demonstrating Positive Effect Protecting DNA From Radiation Exposure

Retrieved on: 
Friday, May 26, 2023
Interventional, DNA, CT, Radiation, Clinical trial, Research, Nuclear medicine, CMO, Angiography, Radiology, CAIR, Capsule, Princess Margaret Hospital, X-ray, Journal, DNA repair, McMaster University, Patient, Physician, Risk, UV, Cell nucleus, University Health Network, FRCPC, Cardiology, FDA, Therapy, Health Canada, Mammography, Air pollution, Smoking, Halo, Radiation exposure, P53, Medical imaging, Dietary supplement

Dr. Kieran Murphy MD, FRCPC, FSIR, Founder, Inventor, and CMO of Cora Therapeutics, announced the efficacy of a proprietary antioxidant complex in safeguarding DNA from radiation exposure during life-saving aortic aneurysm stenting procedures guided by X-ray technology.

Key Points: 
  • Dr. Kieran Murphy MD, FRCPC, FSIR, Founder, Inventor, and CMO of Cora Therapeutics, announced the efficacy of a proprietary antioxidant complex in safeguarding DNA from radiation exposure during life-saving aortic aneurysm stenting procedures guided by X-ray technology.
  • During these high-intensity image-guided procedures, physicians were administered the antioxidant complex as two capsules, one hour prior to exposure.
  • Dr. Murphy's team has successfully demonstrated the protection of mitochondrial DNA from radiation in these subjects, marking a significant milestone in medical literature.
  • Considering that mitochondrial DNA is inherited maternally and is 13 times more vulnerable to radiation than nuclear DNA, this achievement holds tremendous promise.

ASDSA Calls for Enhanced Patient Safety of Medical Devices for Patients with All Skin Types

Retrieved on: 
Thursday, May 25, 2023
Policy, Dermatology, FRCPC, FDA, MD, Patient, Research, Society, Skin, Safety, Medical device, Medical imaging

Schaumburg, IL, May 25, 2023 (GLOBE NEWSWIRE) -- The American Society for Dermatologic Surgery Association (ASDSA) released a new policy position aimed at bringing increased patient safety of medical devices for patients with all skin types.

Key Points: 
  • Schaumburg, IL, May 25, 2023 (GLOBE NEWSWIRE) -- The American Society for Dermatologic Surgery Association (ASDSA) released a new policy position aimed at bringing increased patient safety of medical devices for patients with all skin types.
  • Providing patients with enhanced instructions for using medical devices where diverse skin tones could be impacted.
  • Stating the accepted ranges of values that are normal, borderline or overly concerning / emergent for medical devices, like pulse oximeters, for patients with all skin types.
  • Calling for further research to develop all medical devices, specifically pulse oximetry devices, with all skin types included, and incorporating newer technologies to improve device performance.